Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)

Editas Medicine (EDIT) has reported Restructuring Costs for 2 consecutive years, with $26.1 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Restructuring Costs changed N/A year-over-year to $26.1 million; the TTM figure through Sep 2025 stood at $79.2 million (changed N/A YoY), while the FY2024 annual figure was $12.2 million, changed N/A from the prior year.
• Restructuring Costs declined to $26.1 million in Q2 2025 per EDIT's latest filing, from $40.9 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $40.9 million in Q1 2025 and bottomed at $12.2 million in Q4 2024.